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1. INTRODUCTION 
 
1.1. Chronic Lymphocytic Leukemia 
  
1.1.1. Definition and Epidemiology 
CLL is the most common type of adult leukemia in the western world, accounting for 24% 
of all leukemia’s. The disease occurs at a median age of 65 to 70 years. Over the last years 
the number of younger patients under 60 years has increased, now representing about 
20% of all patients (Diehl et al. 1999, Dighiero et al. 1996). It is also a disease with a 
frequent association in families (10 to 20% of patients have at least one first-degree 
relative with CLL) as well as other cancers (Catovsky 2004).  
 
CLL is renowned for its variable natural history with respect to time to progression and 
response to standard cytotoxic therapies. About one third of the patients never require 
treatment and have a long survival; in another third, an initial indolent phase is followed by 
progression of the disease; the remaining third of the patients seem to have an aggressive 
disease at the onset and need early treatment (Dighiero et al. 2000). 
 
The development of the Rai (Rai et al. 1975) and the Binet (Binet et al. 1981) staging 
systems for CLL has allowed the separation of three prognostic groups: good, intermediate 
and poor prognosis (Binet stages A, B, C). Both systems clearly identify patients with poor 
prognosis who need immediate therapy, but do not predict the risk of early disease 
progression in the good prognosis group. The Binet stage A comprises approximately two 
thirds of patients, who have a median age of 64 years and an expected median survival of 
>10 years, which is close to the life expectancy of a normal population matched for sex 
and age (Dighiero et al. 1998) 
 
The median survival of patients with CLL ranges from 5 to 10 years, but a trend to a longer 
survival has become evident in the last years, partially due to earlier diagnosis (Brugiatelli 
et al. 2006) 
 
1.1.2. Pathogenesis 
CLL is characterized by the progressive accumulation of monoclonal peripheral (mature, but 
immune incompetent) B-Cells in peripheral blood, lymphoid tissues, bone marrow, and 
spleen. The monoclonal population of B-Cells in CLL expresses CD19, CD5, and CD23 on 
the surface (Chiorazzi et al. 2005). 
Chromosomal aberrations occurs in 82% of CLL-cases, the most common is the deletion at 
13q with 55% and it is associated with a long interval between diagnosis and the need for 
treatment (the treatment-free interval). The deletion at chromosome 11q is at second 
place with 18 %, trisomy 12q follows with 16 %, whereas the deletion at 17p (7%) and 6q 
(6%) are seldom.  
10-17 % of the CLL-patients have a mutation at the p-53 gen, which regulates DNA 
repairing and apoptosis. These patients have a highly increased risk of progression, as the 
p-53 mutation, mostly to be found in Binet C Stadium, is the strongest negative prognosis 
factor for the survival (Döhner et al. 2000). Moreover, the anti-apoptotic BCL2 gene is 
reported to be over expressed in 65 to 70% of B-CLLs (Korz et al. 2002). 
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1.1.3. Clinical Symptoms 
CLL is a disease which progresses slowly and it is until now not fully curable. The cardinal 
symptoms are: Lymph nodes swelling, hepatomegaly, splenomegaly and leucocytosis. The 
bone marrow suppression through the CLL-cells causes in later stages anemia and 
thrombocytopenia. Many patients suffer from unspecific symptoms such as fatigue and 
infections caused by the hematopoietic insufficiency. B-symptoms like fever, night sweats, 
and weight loss are in 20% of the cases at the time of diagnosis present. 
Principal causes of death in CLL cases are infections (pneumonia and sepsis) and second 
malignancies. 
 
1.1.4. Disease-associated Complications 
Further complications in the course of the disease are AIHA (autoimmune hemolytic 
anemia) in 15-20% of the cases, autoimmune thrombocytopenia, and the „pure red 
cell“anemia (Mauro et al 2000). 
A transformation into a high malignant Non-Hodgkin-Lymphoma (the so-called Richter-
syndrome) or into an acute lymphoblastic leukemia occurs seldom.  
CLL patients show furthermore an increased tendency to produce second malignancies such 
as bronchial carcinoma, malignant melanoma, and malignant tumors from the gastro-
intestinal-tract (Travis et al 1992, Dighiero et al 1998). 
 
1.1.5. Diagnostic Procedures 
Following criteria, based on the ESMO (European Society for Medical Oncology) clinical 
recommendations (Eichhorst et al. 2008) are newer than the ones based on the Guidelines 
published in 1996 by NCI-WG (National Cancer Institute-Sponsored Working Group) and 
are important for the clinical diagnosis of CLL :  
 
 Peripheral Blood 
1. Sustained increase of peripheral blood lymphocytes > 5x109 cells/l not explained 
by other clinical disorders. 
2. Predominance of small, morphologically mature lymphocytes in the blood smear.  
 
 Bone Marrow Examination 
A bone marrow aspirate and biopsy are generally not required to come to the diagnosis 
of CLL. But it is not to forget that basically CLL is a disease of the bone marrow, and it 
is therefore appropriate and recommended to evaluate the involvement of the bone 
marrow. The aspirate smear must show >30% of all nucleated cells to be lymphoid. A 
bone marrow examination also provides useful prognostic information by determining 
whether there is a diffuse or non diffuse involvement (Rozman et al. 1984), and permits 
an assessment of the erythroid precursors and megakaryocytes. 
 
 Immunphenotype 
The composite immunphenotype CD5+, CD19+, CD20+(low), CD23+, sIG low, CD79b 
low, FMC7- allows the distinction of most cases of B-cell type CLL from other CD5+ B-
cell lymphoma.  
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1.1.6. Staging Systems 
The fact that some patients with CLL could survive for many years without therapy and 
eventually succumb to unrelated diseases, whereas others have a rapidly fatal disease 
despite aggressive therapy led Rai and colleagues (Rai et al. 1975, 1987) and Binet and 
colleagues (Binet et al. 1981) to develop devised staging systems for use in assessing the 
extent of disease in an individual patient. Both are based on the extent of 
lymphadenopathy, splenomegaly, and hepatomegaly on physical examination and on the 
degree of anemia and thrombocytopenia in peripheral cell counts. These simple 
examinations are inexpensive and can be applied to every patient without special or 
complicated technical equipment. 
 
These systems remain the cornerstones on which decisions regarding medical follow-up 
and treatment are built, but they have some limitations, the most important of which is 
their inability to distinguish between patients with early disease who will remain stable for 
many years and require no therapy and those who will develop progressive disease and 
require treatment, in other words, they fail to predict the course of the disease in patients 
in whom CLL is diagnosed in early stages (Molica 1991). 
 
Below are described both the established staging systems of CLL according to Rai (Rai et 
al. 1975) and Binet (Binet et al. 1981) 
 
Table 1: Rai staging of CLL (Rai et al. 1975)   
Stage Definition Survival rate 
Low risk  > 10 years 
0 Absolute lymphocytosis >15.000/µl  
 Bone marrow infiltration >40 %  
   
Intermediate risk  7 years 
I Absolute lymphocytosis with lymphadenopathy   
II Absolute lymphocytosis with either hepatomegaly or 
splenomegaly (with or without lymphadenopathy)  
 
   
High risk  2,3 – 5 years 
III Absolute lymphocytosis and anemia (Hb <11 g/dl) 
(with or without lymphadenopathy, hepatomegaly, or 
splenomegaly)  
 
IV Absolute lymphocytosis and thrombocytopenia 
(<100.000/mm3) with or without lymphadenopathy, 
hepatomegaly, splenomegaly, or anemia  
 
 
 
 
 
 
 
 
 
1. Introduction                                                                                                                                                   
4 
 
Table 2: Binet staging of CLL (Binet et al. 1981)   
Stage Definition Survival rate 
Low risk  > 10 years 
A Hb >10 g/dl  
 Platelet count normal  
 Less than three areas of lymphoid enlargement*  
   
Intermediate risk  7 years 
B Hb >10 g/dl  
 Platelet count normal  
 Three or more areas of lymphoid enlargement*  
   
High risk  2,3 – 5 years 
C Hb <10 g/dl and/or Platelet count <100.000/mm3  
regardless of the number of areas of lymphoid 
enlargement*
  
 
*Lymphoid areas include cervical, axillary, inguinal (>1cm) unilateral or bilateral, liver, and 
spleen. 
 
Both Rai’s stage 0 and Binet’s stage A consist of patients with a long survival, the median 
survival time exceeding 10 years. Binet’s stage A comprises 66% of CLL patients (all Rai’s 
stage 0, about 2/3 Rai’s stage I, 
1/3 Rai’s stage II, and 
1/5 Rai’s stage III) with a 78% 5-year 
survival rate, while Rai’s stage 0 comprises 31% of CLL patients with an 82.5% 5-year 
survival rate (FCGCLL 1988). 
 
An exception does exist, however, with the so called “smouldering CLL”, which includes 
around one-third of all CLL patients in Binet stage A. Based on the fact that progression 
strongly affects the overall survival of the patients, also considering the importance of 
adapting therapy to the severity of the disease and not to forget the potential harmful 
effect of  chemotherapeutic agents for the patients, it is understandable that it is important 
to define criteria to identify a subgroup of patients with Binet A (or Rai 0) with low 
probability of disease progression and death. In 1998, Montserrat et al first proposed the 
“smouldering CLL” with the criteria needed to identify it (see table below).  
“Smouldering CLL” is seen as the mild variant of the CLL Binet stage A with a survival rate 
equivalent to an age- and sex-matched normal population; this is of clinical relevance 
because patients with it require therefore no treatment unless progression takes place 
(Montserrat et al 1988, Cheson 1996, FCLLG 1990). 
 
Table 3: smouldering CLL; criteria 
Criteria for Smouldering CLL 
1. CLL Binet stage A 
2. Non-diffuse bone marrow histology 
3. Lymphocyte doubling time (LDT) > 12 months 
4. Hemoglobin level > 13 g/dl 
5. Absolute lymphocyte count < 30.000/ µl 
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1.1.7. Prognostic factors 
Little is known regarding the initiation and progression of CLL (Bullrich et al. 2001). 
Nevertheless, several factors that can predict the clinical course have been identified 
(Rassenti et al. 2004, Crespo et al. 2003, Orchard et al. 2004, Damle et al. 1999, Hamblin 
et al. 1999). Cases in which the leukemic cells have few or no mutations in the 
immunoglobulin heavy-chain variable-region (IgVH) gene or a high level of expression of 
the 70-kD zeta-associated protein (ZAP-70) show an aggressive course, whereas cases 
involving mutated CLL clones or few ZAP-70 cells show an indolent course (Chiorazzi et al. 
2005). Genomic aberrations in CLL are also independent predictors of disease progression 
and survival (Döhner et al. 2000). However, the molecular basis of these associations is 
largely unknown.  
 
Neither the Rai nor the Binet staging system can predict which patients among the early 
stage prognosis group will shift into progressive disease. Lymphocyte doubling time, serum 
levels of ß2-microglobulin, thymidine kinase (Hallek et al. 1996), soluble CD23 (Sarfati et 
al. 1996), as well as CD38 expression on malignant cells (Damle et al. 1999) can help 
predict disease activity and rapid progression, but the presence of cytogenetic 
abnormalities like 11q or 17p deletions in the leukemic B-cells (Döhner et al. 2000) or 
somatic mutations in the immunoglobulin heavy chain genes (Damle et al. 1999, Hamblin 
et al. 1999) are better predictors of survival. A retrospective study from the French 
Cooperative Group on 146 patients for whom the Ig sequence could be obtained and with a 
long follow-up stressed the importance of the mutational profile of Ig genes in predicting 
the progression in Stage A patients. Stage A patients expressing mutated Ig genes have a 
75% 12-year survival and a progression free survival of 156 months, as compared to a 
median overall survival of 97 months and a progression free survival of 42 months in those 
without them. 
 
These results suggest that a high percentage of stage A patients requiring early treatment 
are included within this group. However, this study also showed that a small percentage of 
mutated cases (about 10%) may also require early treatment and may die from disease 
related causes (Vanconcellos et al. 2003). These data confirm the results of a monocentric 
German study which represents the greatest Binet stage A population so far with 189 
patients. The estimated median overall survival time of the group with IgVH homology of 
98% or greater was 79 months whereas the median OS was 152 months for the group with 
IgVH homology less than 98% (Kröber et al. 2002).  
 
A recent preliminary analysis performed on a common data base of the German and French 
cooperative study groups identified short LDT and high sTK as the strongest predictors of 
rapid progression. Nonetheless, a model testing the four following parameters (sTK, LDT, 
mutational status and unfavorable cytogenetic) was accurate to segregate low and high risk 
of progression when high risk was defined as two or more factors of bad prognosis.  
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In order to give an easier and clearer overview, below are once again listed in the table 
some established additional parameters which serve to help predict the prognosis of CLL 
patients in common.  
 
Table 4: CLL Prognostic Parameters (Hallek 2006) 
CLL Prognostic Parameters 
1. Aberrations in chromosomes 13(13q-), 11(11q-) and 17(17p-)      Döhner 2000,  Cheson et al. 1996 
2. Cytoplasmic ZAP70 in CLL cells                              Moreton et al. 2005, Wendtner et al. 2004 
3. Expression of CD38 on CLL cells                                 Bosch et al. 2002, Anaissie et al. 1998 
4. LDT (Lymphocyte Doubling Time)                          Montserrat et al. 1986, Plunkett et al. 1993 
5. Serum ß2-microglobulin concentration                                                     Rai et al. 2000 
6. Serum levels of soluble CD23                                  Johnson et al. 1996, Leporrier et al. 2001 
7. Serum thymidine kinase activity                                                          Hallek et al. 2004 
8. 
Somatic hypermutations of the  
immunoglobulin VH-gene region                                  Bosch et al. 2002, O”Brien et al. 2001 
 
 
1.1.8. Treatment Options 
A therapy is recommended to be commenced in CLL patients with Binet stage C or Rai 
stage III/IV and also in patients having lower CLL stage (Binet A & B, Rai II) with active 
disease (for example B-symptoms, rapid lymphocyte doubling time, anemia or 
thrombocytopenia). Active disease should be clearly documented for protocol therapy and 
the following criteria must be met (Cheson 1996): 
 
1. A minimum of any one of the following disease-related symptoms must be present:  
(a) Weight loss >10% within the previous 6 months  
(b) Extreme fatigue (i.e. ECOG PS 2 or worse; cannot work or unable to perform 
usual activities) 
(c) Fevers of greater than 100.5oF for >2 weeks without evidence of infection 
(d) Night sweats without evidence of infection 
2. Evidence of progressive marrow failure as manifested by the development of, or 
worsening of, anemia and/or thrombocytopenia 
3. Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid 
therapy 
4. Massive (i.e. >6 cm below the left costal margin) or progressive splenomegaly 
5. Massive nodes or clusters (i.e. >10 cm in longest diameter) or progressive 
lymphadenopathy 
6. Progressive lymphocytosis with an increase of >50% over a 2-month period, or an 
anticipated doubling time of less than 6 months 
7. Marked hypogammaglobulinemia or the development of a monoclonal protein in the 
absence of any of the above criteria for active disease is not sufficient for protocol 
therapy 
 
Patients with smouldering CLL should not (as already stated above) be offered therapy until 
they exhibit clear evidence of disease progression.   
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Chlorambucil 
Chlorambucil, an aromatic derivative of nitrogen mustards taken orally, was first introduced 
for the treatment of CLL in 1952 and has since then established itself as the most common 
treatment for CLL for around 30 years (Foon et al. 1987), although its beneficial role has 
never been proved. A large randomized clinical trial (FCGCLL 1990) compared the usage of 
daily Chlorambucil with the “watch and wait” strategy. It could be demonstrated that 
Chlorambucil has a beneficial effect in terms of 9-month remission and of preventing 
disease progression to stage B. However, no benefit was observed in terms of overall 
survival, and a harmful effect can be evoked since Chlorambucil seems to favor the 
occurrence of epithelial cancers and increase resistance to further treatment among those 
patients with disease progression. It is also clear that Chlorambucil is able to prevent 
disease progression to stage B but it does not appear to affect progression to stage C. 
 
The appearance of purine analogs has opened a new page in the treatment of CLL. Two 
large randomized studies (Rai et al. 2000 and Eichhorst et al. 2003) and a metaanalysis of 
randomized studies (Zhu et al. 2004), proved that Fludarabine, used as single agent and 
compared with Chlorambucil at standard doses, induced higher complete response rates 
and improved patients' quality of life, irrespectively of age. Even the combination of 
Cyclophosphamide, Adriamycin, and Prednison (CAP) is still inferior in terms of the number 
of complete remissions and the duration of remission in first- and second-line treatment of 
CLL (FCGCLL 1996, Leporrier et al. 2001). However, none of these studies could 
demonstrate a benefit on median overall survival.  
 
One study initiated by the German CLL study group (CLL-5-study) intended to evaluate the 
effect of Fludarabine versus Chlorambucil in first line therapy of elderly patients above the 
age of 65 years with advanced CLL, because it was not clear if elderly or physically non-fit 
patients would benefit from more intense first line strategies as well (this was the reason 
why Chlorambucil is still widely used in first line therapy of elderly CLL patients). The result 
showed that elderly patients have no significant clinical benefit from first line therapy with 
Fludarabine in comparison to Chlorambucil. Despite being able to induce higher CRR and 
ORR Fludarabine failed to show any benefit in terms of PFS and OS. Chlorambucil and 
Fludarabine therefore represent themselves as similar potent first-line treatment options 
for elderly CLL patients (Eichhorst et al. 2009). 
 
Fludarabine 
Fludarabine (Fludara®) is distributed in Germany by the company Bayer Schering Pharma 
AG. It is the best studied purine analogue used for the treatment of CLL. Fludarabine is 
available in injection vials containing 50 mg dry substance. A fluorinated adenine (active 
ingredient: Fludarabine-dihydrogen phosphate) and thus by definition an antimetabolite, 
Fludarabine acts by inhibiting DNA synthesis. The recommended adult dose of Fludarabine 
is 25 mg/m2 administered intravenously over a period of approximately 30 minutes daily for 
five consecutive days. Each 5 day course of treatment should commence every 28 days. 
Dosage may be decreased or delayed based on evidence of hematologic or non-
hematologic toxicity. Physicians should consider delaying or discontinuing the drug if 
neurotoxicity occurs. Dose reduction (20%) is needed for adult patients with moderate 
impairment of renal function (creatinine clearance 30-70 ml/min/1.73m2). Severely 
impaired renal function (creatinine clearance less than 30 ml/min/1.73m2) prohibits the use 
of Fludarabine.   
 
The major side effects are myelosuppression with neutropenia and immunosuppression and 
reduction of the T-helper cells, at higher doses CNS toxicity. Mucositis/stomatitis, diarrhea, 
anorexia, nausea, vomiting, and elevation of transaminases are also possible (Adkins et al. 
1997, Pott et al. 1997). 
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Myelosuppression may be severe, cumulative, and may affect multiple cell lines. Bone 
marrow fibrosis occurred in one CLL patient, several instances of trilineage bone marrow 
hypoplasias or aplasias resulting in pancytopenia, sometimes resulting in death, were also 
reported. Life threatening and sometimes fatal autoimmune phenomena such as hemolytic 
anemia, autoimmune thrombocytopenia / thrombocytopenic purpura (ITP), Evan’s 
syndrome, and acquired hemophilia were also reported. Steroids may or may not be 
effective in controlling these hemolytic episodes. The majority of patients re-challenged 
with Fludarabine developed a recurrence in the hemolytic process. The mechanism(s) which 
predispose patients to the development of this complication has not been identified. 
Discontinuation of therapy with Fludarabine is therefore recommended in case of 
hemolysis.  
 
Serious and sometimes fatal infections, including opportunistic infections and reactivations 
of latent viral infections such as VZV (herpes zoster), Epstein-Barr virus, JC virus 
(progressive multifocal leukoencephalopathy) have been reported in patients treated with 
Fludarabine. 
 
When used at high doses in dose-ranging studies in patients with acute leukemia, 
Fludarabin was associated with severe neurologic effects, including blindness, coma, and 
death. This severe CNS toxicity occurred in 36% of patients treated with doses 
approximately four times greater (96 mg/m2/day for 5-7 days) than the recommended 
dose. Similar severe CNS toxicity, including coma, seizures, visual disturbances, optic 
neuropathy, optic neuritis, blindness, objective weakness, agitation and confusion have 
been reported in patients treated at doses in the range of the dose recommended for CLL. 
 
Skin toxicity, consisting primarily of skin rashes has been reported. Erythema multiforme, 
Stevens-Johnson syndrome, toxic epidermal necrolysis, and pemphigus have also been 
reported, with fatal outcomes in some cases. Worsening or flaring up of pre-existing skin 
cancer lesions, as well as new onset of skin cancer was also noted.  
 
Based on its mechanism of action, Fludarabine phosphate can cause fetal harm when 
administered to a pregnant woman. Fludarabine phosphate was embryolethal and 
teratogenic in both rats and rabbits. If it is used during pregnancy, or if the patient 
becomes pregnant while taking this drug, the patient should be apprised of the potential 
hazard to the fetus. Woman of childbearing potential should be advised to avoid becoming 
pregnant. Women of childbearing potential and fertile males must take contraceptive 
measures during and at least for six months after cessation of treatment with Fludarabine. 
 
Retrospective cohort studies showed that Fludarabine did not increase the rate of 
secondary cancers, as compared to the rate in untreated patients. However, Fludarabine 
has some drawbacks, such as the increased risk of opportunistic infections, the occurrence 
of Fludarabine-associated autoimmune hemolytic anemia (AIHA), and decreased stem cell 
mobilization although data’s supporting this remain controversial. 
 
Actual recommendations suggest that patients without co-morbidity should receive 
Fludarabine plus Cyclophosphamide, whereas elderly and unfit patients with co-morbidity 
(in particular renal insufficiency) Chlorambucil or alternatively a dose-reduced Fludarabine 
monotherapy, which appear to be less myelotoxic than the FC combination. Younger 
patients with unfavorable biological risk factors should be considered for high-dose 
chemotherapy and autologous or allogeneic stem cell transplantation within approved 
clinical trials. Patients who are refractory or relapsed after first-line Chlorambucil should 
receive Fludarabine-containing regimens. Patients either relapsing soon (within one year) 
after or not responding to Fludarabine-based chemotherapy should be considered for 
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schedules including non-cross-reactive agents, such as Alemtuzumab, possibly followed by 
high-dose chemotherapy and autologous transplantation in the context of a clinical trial or 
by allogeneic stem cell transplantation (Brugiatelli et al. 2006). 
 
Considering the possible, not to be underestimated adverse events due to Fludarabine 
administration, patients undergoing therapy should be closely observed for signs of 
hematologic and non hematologic toxicity. Periodic assessment of peripheral blood counts is 
recommended to detect the development of anemia, neutropenia and thrombocytopenia.  
In patients with impaired state of health, Fludarabine should be given with caution and 
after careful risk/benefit consideration. This applies especially for patients with severe 
impairment of bone marrow function (thrombocytopenia, anemia, and/or granulocyto-
penia), immunodeficiency or with a history of opportunistic infection. Prophylactic 
treatment should be considered in patients with increased risk of developing opportunistic 
infections.   
 
In a clinical investigation using Fludarabine in combination with Pentostatin 
(deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia, there was 
an unacceptably high incidence of fatal pulmonary toxicity. The use of Fludarabine in 
combination with Pentostatin is therefore not recommended. 
 
Response rates were further improved by Fludarabine-containing combination regimens, 
especially by the Fludarabine plus Cyclophosphamide combination, which was shown to 
have a higher efficacy with a higher rate of overall response rate and more complete 
remissions than Fludarabine alone also in subgroups at higher risk, such as patients with 
del(17) or p53 mutation. The same study also showed that the FC (Fludarabine and 
Cyclophosphamide) has an edge against Fludarabine alone regarding the progression-free 
survival time and the treatment-free survival time. Thus far, no difference in median overall 
survival has been observed, suggesting that a longer median observation time (in this 
study 22 months) is needed to determine a survival benefit for any first-line treatment 
(Eichhorst et al. 2006). 2 other publications in 2007 by Catovsky et al. (Fludarabine / 
Chlorambucil vs. Fludarabine + Cyclophosphamide) and Flinn et al. (Fludarabine vs. 
Fludarabine + Cyclophosphamide) confirmed the data of the trial conducted by Eichhorst et 
al. FC was since then the standard first-line therapy in CLL patients who are physically fit 
until the era of RFC (Rituximab, Fludarabine, and Cyclophosphamide), which began 2008 
and was marked by the emergence of Rituximab as a powerful option.  
 
Rituximab (Mabthera®), an anti-CD20 monoclonal antibody was a surprise newcomer in the 
so far established therapy regime. Somewhat surprisingly, combinations of Rituximab with 
other chemotherapy agents have proven to be very efficacious, thus, could possibly prevail 
to be the new standard in the CLL therapy in the future. There is preclinical evidence for 
synergy between Rituximab and Fludarabine (Di Gaetano et al. 2001). A large phase II trial 
conducted at the MD Anderson Cancer Center showed that the combination of FCR 
(Fludarabine, Cyclophosphamide, and Rituximab) showed superior response rates and 
complete remission rate than the FC alternative (Keating et al. 2005). This result, together 
with some other studies suggests that Rituximab plus Fludarabine-based therapies, in 
particular the FCR combination represent a significant advance in the therapy for CLL.  
 
CLL8-trial initiated by the German CLL study group confirms those previous trials and 
proved the efficacy of the highly anticipated FCR by comparing it with FC in totally 817 
patients within a randomized trial. The trial found that treatment with FCR 
chemoimmunotherapy improves response rates and progression free survival when 
compared to the FC chemotherapy. The result is decisive, as it sets now a new standard in 
CLL therapy for physically fit patients, which is FCR (Fludarabine, Cyclophosphamide, and 
Rituximab) (Hallek et al. 2008)  
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1.2. Rationale and study purpose 
 
The fact that today CLL is increasingly diagnosed within young patients (11% are younger 
than 55 years) and in early stages shows a very inhomogeneous patient group regarding 
its illness course and progression risk. It has also been agreed, that patients with 
smouldering-CLL will not be treated because of their almost normal survival rate. It is 
possible to identify using new parameters a risk-group under the remaining stage A 
patients, which is very likely to suffer progression within 12 months (Hallek et al. 1997).  
 
Based on the hypothesis that qualitatively good complete remission leads to prolonged free 
of illness interval and overall survival, this study aims to verify whether a therapy with 
Fludarabine, today the backbone substance for CLL therapy, would prevent or at least delay 
the progression of the high risk patients in early stages of CLL. The CLL-1 protocol (a 
multicentre, risk stratified and randomized Phase III study) was therefore designed. The 
reason for the risk stratification is first of all to prevent needless therapy for patients with 
indolent CLL and secondly to make sure that only patients who anyway within 2 years 
should receive treatment, would be treated. (Hallek et al. 1997) 
 
Patients who are stratified within the HR (High risk) group are in a second step randomized 
to “upfront” Fludarabine or “Watch and Wait” strategy until progressive disease occurs. The 
quality of the remission, the progression free survival, the overall survival will all then be 
evaluated.  
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2. MATERIALS AND METHOD 
 
2.1. CLL-1-Protocol: Study Design 
 
Below is the simplified design of the CLL-1 study described, the complete flow sheet of the 
study is in appendix 2 (see chapter 9.2).  
 
 
Fig.1. Simplified study design 
 
This is a multicentre, risk stratified trial evaluating the therapy and prognosis factors of CLL 
in Binet stage A patients. It consists of one group which includes all patients with low 
progression risk, and another group for all patients with high progression risk. The group 
consisting of high risk patients would then be divided into 2 cohorts after a phase III 
randomization (1:1) in order to compare the Fludarabine therapy with the standard option, 
which is observation without therapy (the so called “Watch and Wait” strategy). 
 
Following questions should be answered:  
 
1) Is it possible to extend the progression free survival and the overall survival of CLL 
patients in Binet A through an early, risk adapted Fludarabine therapy? 
 
2) How significant is the role of the new prognosis factors for CLL patients in Binet A? 
Parameters defining high progression risk: 
 
Non-nodular bone marrow infiltration or  
LDT <12 months  
          And 
Serum Thymidine Kinase >7.0 U/l or  
Serum-ß2-microglobulin >3.5 mg/l. 
Parameters defining low progression risk: 
 
Non-diffuse bone marrow infiltration or  
LDT >12 months  
          And 
Serum Thymidine Kinase <7.0 U/l or  
Serum-ß2-microglobulin <3.5 mg/l. 
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2.1.1. Protocol for risk-adapted therapy of CLL in the Binet stage A  
The Binet A patients are assessed in terms of their progression risk with bone marrow 
histology (infiltration type), lymphocyte doubling time (LDT), serum thymidine kinase, and 
the serum-ß2-microglobulin. High progression risk is defined as:  
 
 
Not-nodular bone marrow infiltration or  LDT < 12 months 
 
and 
 
Serum Thymidine Kinase > 7.0 U/l or Serum-ß2-microglobulin > 3.5 mg/l 
 
 
Patients with high progression risk would then after randomization either receive treatment 
with Fludarabine in a controlled trial (cohort I) or only be observed (cohort II), whereas the 
patients without high progression risk according to the definition above (cohort III) would 
not be treated but observed. 
 
Within this analysis only patients with high risk for progression are assessed.   
 
2.1.1.1. Objectives 
 Primary Objective 
Progression free survival 
 
 Secondary Objectives 
- Overall survival 
- Therapy efficacy (CR, PR, SD, Progression, remission duration) 
- Adverse events related to treatment (treatment safety) 
- Occurrence of infections 
- Quality of life 
  
2.1.2 Assessment of the significance of new prognosis factors for CLL patients in     
Binet stage A 
 
Following parameter assessments are needed at inclusion time to the study in order to 
analyze the prognosis factors: 
 
• Age 
• Gender 
• Binet-stage 
• Rai-stage 
• Peripheral blood lymphocyte 
• Hemoglobin 
• Blood platelets 
• Bone marrow histology and cytology 
• Lymph node histology, when lymph node enlargement with at least 2 cm diameter 
exists and a punction (with small risk) is possible (including assessment of the 
histological subtype of B-CLL and B-CLL with plasmacellular differentiation) (Harris et 
al 1994) 
• Lymphocyte doubling time 
• Serum immunoglobulin level (IgA, IgM, IgG) 
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• Serum-ß2-microglobulin 
• Serum thymidine kinase 
• Serum LDH 
• Serum albumin 
• Number of lymph node enlargements through clinical examination plus chest X-ray 
plus abdominal ultrasound 
• Hepatomegaly 
• Splenomegaly 
• Molecular cytogenetic with FISH method (e.g. p53-mutation, 11q-deletion)  
• B-symptoms 
• ECOG performance status 
 
2.1.2.1. Objectives 
 Primary objective 
Progression free survival 
 
 Secondary objective 
Overall survival 
 
2.2. Study Population 
2.2.1. Inclusion Criteria (Cheson et al. 1996) 
 
1. Established diagnosis of B-CLL in Stage Binet A. 
The diagnosis criteria for B-CLL are: 
-  Permanent (>3 months) absolute lymphocytosis >5000/µl in the peripheral blood. 
- >30% mature lymphocytes in bone marrow. 
- Immunphenotype confirmation of the diagnosis in the form of low expression of 
surface immunoglobulin, CD5+, CD19+, CD20+, CD23+, inclusive CD5/CD19 
(Matutes et al 1994, Rozman et al 1995). 
2. First diagnosis within 3 years before inclusion in study. 
3. No previous CLL therapy. 
4. Age between 18 and 75 years old. 
5. ECOG performance status 0-2. 
6. No insufficiency of important organ functions. 
7. Written informed consent of patient for participation in the study. 
8. Presence of all necessary parameters for risk stratification. 
9. Willingness to accept contraception if randomized to cohort I during the therapy. 
 
2.2.2. Exclusion Criteria (Cheson et al. 1996) 
 
1. Age under 18 years old and over 75 years old. 
2. ECOG performance status >2. 
3. Clinically apparent immune hemolysis. 
4. Positive Coombs test. 
5. Clinically apparent immune thrombocytopenia. 
6. Active secondary malignancy. 
7. Chemotherapy/radiotherapy for any neoplastic disease other than B-CLL prior to the 
study. 
8. HIV-infection. 
9. Pregnancy and/or nursing. 
10.Participation in another trial before and during the study. 
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11.Concurrent severe diseases, as listed following:  
- Clinical apparent heart insufficiency 
- Cardiomyopathy 
- Myocardial infarction within the past 6 months prior to the study 
- Severe chronic obstructive lung disease with hypoxemia 
- Severe diabetes mellitus 
- Hypertension difficult to control 
- Infection hard to control 
- Impaired liver function with serum bilirubin >2mg/dl and/or Transaminase over 3-
times of ULN 
- Impaired renal function with creatinine >3 mg/dl 
- Clinically apparent cerebral dysfunction 
- Severe neurological or psychiatric diseases which hinder a good cooperation 
 
2.3. Protocol Schedule 
 
2.3.1. Procedures of risk stratification and randomization 
The first step following after the registration is the assessment of lymphocyte doubling time 
(LDT) by the study center; at least 4 blood lymphocyte counts are therefore needed. Bone 
marrow histology is also important to evaluate the infiltration. These two parameters, 
together with serum thymidine kinase and serum-ß2-microglobulin, would then be used to 
perform risk stratification in order to determine whether the patients high progression risk 
have or not. Patients stratified to the high risk group will furthermore be randomized 
between the treatment arm (cohort I) and the watch and wait arm (cohort II). 
 
2.3.2. Treatment Schedule 
2.3.2.1. Remission Criteria 
The remission status is evaluated according to a modified version of the NCI sponsored 
Working Group guidelines (Cheson 1996, 1998), therapy results are compared with initial 
status at study inclusion, not at the beginning of therapy. 
 
Complete Remission (CR) 
Following criteria must for at least 2 months be met: 
 Lymph nodes <1 cm (previous lymph nodes enlargement no more detectable), 
evaluated by clinical examination, chest x-ray, abdomen ultrasound and in case of 
doubt CT-scan. 
 Normal liver and spleen sizes. 
 Absence of disease related symptoms. 
 Peripheral blood lymphocytes <4.000/µl. 
 Peripheral blood neutrophils >1.500/µl. 
 Platelets >100.000/µl. 
 Hemoglobin >11g/dl (untransfused). 
 Bone marrow lymphocytes <30%. 
 
Patients with CR, who however still has bone marrow nodules (histological), are given the 
remission status nCR (nodular complete remission). 
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Partial Remission (PR) 
The definition of a partial remission requires all of the following features (if abnormal prior 
to therapy) for at least 2 months: 
 >50% decrease in peripheral blood lymphocyte count from the pretherapeutic 
staging. 
 >50% reduction in lymphadenopathy. 
 >50% reduction of the size of the enlargement of liver and/or spleen. 
 
As well as one or more of the remaining features: 
 ANC >1.500/µl or 50% improvement over baseline. 
 Platelets >100.000/µl or 50% improvement over baseline. 
 Hemoglobin >11 g/dl or 50% improvement over baseline without transfusions. 
 
Progression (PD) or relapse 
Progression occurs when at least one of the following criteria is met:  
 Progression to symptomatic stage Binet B or stage Binet C. 
 Progressive lymphocytosis with an increase of >100% (doubling) of the absolute 
lymphocyte count. 
 Transformation into a highly aggressive NHL (Richter-syndrome) or into 
Prolymphocytoid leukemia (>55% Prolymphocytes). 
 25% size enlargement of liver and spleen or new evidence of previously not detected 
hepato/splenomegaly (confirmed by ultrasound examination). 
 Evidence of new lymph node enlargement (at least 1 cm diameter) in 2 consecutive 
examinations with at least 2 weeks interval between them. 
 Clear lymph node enlargement, at least to the double (100%) of the previous size in 
2 consecutive examinations with at least 2 weeks time in between. One of the lymph 
nodes must have at least 2 cm diameter. 
 
Stable Disease (SD)  
Stable Disease (SD) is defined as the remission status if the criteria for Complete 
Remission (CR), Partial Remission (PR), and Progression (PD) are not met. 
 
2.3.2.2. Guideline for concomitant supportive therapy 
Patients should receive full supportive care including transfusions of blood and blood 
products, antibiotics, anti-emetic drugs etc when they are reasonably needed. Concomitant 
antiemetic treatment with Metoclopramide (e.g. Paspertine) 2 x 1 vial i.v. daily during the 
Fludarabine therapy is highly recommended. Common, adequate hygiene measures are 
sufficient for infection prophylaxis. Prophylactic administration of antibiotics and G-CSF 
(e.g. Neupogen®) or other hematopoietic growth factors are not required.  
 
2.3.2.3. Dose Modification  
Following adverse effects indicates for dose reduction of Fludarabine during the next cycles: 
 Occurrence of severe common infections during the neutropenia phase after the 
application of Fludarabine: 25 % dose reduction 
 Occurrence of severe neutropenia (if it didn’t occur before therapy): 
Nadir of neutrophile < 500/µl: 50 % dose reduction 
Nadir of neutrophile < 1000/µl: 25 % dose reduction 
 Occurrence of severe thrombocytopenia (if it didn’t occur before therapy): 
Nadir of platelet count < 20.000/µl: 50 % dose reduction 
Thrombocytopenia and simultaneous bleeding complications: 50 % dose reduction 
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2.3.2.4. Criteria for therapy termination 
Treatment with Fludarabine is stopped precociously in case of: 
 Lack of response or disease progression after 2 cycles. 
 Occurrence of severe adverse effects, especially life threatening complications. 
 
No further chemotherapy is scheduled after the discontinuation until reasonable indications 
show up.  
 
2.3.3. Procedures for patients having the “watch and wait” strategy (cohort II & III) 
Patients stratified to the group with low progression risk (cohort III) and therefore counted 
among the control arm or patients randomized to the control arm of the study despite 
having high progression risk (cohort II) receive no chemotherapy, but would only be 
evaluated according to the „watch and wait“ strategy until the occurrence of therapy 
indications. 
 
2.3.4. Treatment guidelines for progressive/relapsed patients 
Indications for treatment due to progression/relapse are defined as following (Hellriegel 
1997): 
 
 Progression to stage Binet C or symptomatic stage Binet B. 
 Progression with continuous increase of absolute lymphocyte count >100% and/or 
increase of leukocyte count >300.000/µl.  
 Development of severe B-symptoms. 
 
Patients included in the „watch and wait“arm (cohort II and III) would, in case of therapy 
indications, be included into the CLL4-Study (Fludarabine vs. combination of Fludarabine-
Cyclophosphamide) if they are under 65 years old. Patients over 65 years old would be 
included into CLL5-Study (Fludarabine vs. Chlorambucil). 
 
On the other hand, cohort I patients with progression or relapse after Fludarabine therapy 
should receive further treatment according to the CLL6-Protocol (therapy combination 
consisting Fludarabine, Cyclophosphamide, and Mitoxantrone).  
 
In case the patients reject the therapy above, it is allowed to treat them with Fludarabine, 
unless they have history of no-response under Fludarabine therapy. 
 
2.3.5. Interim staging, final staging, and follow-up evaluation in cohort I 
Interim staging is scheduled after 2 and 4 cycles of therapy (month 2 and 4), whereas the 
final staging is scheduled after 6 cycles, more precisely it is scheduled 2 months after the 
last Fludarabine cycle (month 8). Follow-up evaluations after the final staging are 
performed at months 9, 12, 18, and 24 (end of study) and annually thereafter.  
 
2.3.6. Follow-up evaluation in cohort II and III 
For patients belonging to cohort II and III the follow-up evaluations are scheduled at 
months 3, 6, 9, 12, 18, 24 and annually thereafter.   
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2.4. Statistic Analysis 
2.4.1. Progression Free Survival (PFS) and Overall Survival (OS) 
The analysis of the progression free survival and overall survival will be estimated using the 
Kaplan-Meier product-limit estimator. Log-rank test would also be used to analyze the 
survival curves. The level of significance (one sided test) is at 5 %. 
 
2.4.2. Efficacy of the Fludarabine therapy 
The efficacy of Fludarabine will be evaluated on the patients who did receive Fludarabine. 
The analysis of the response rate (Occurrence of CR, PR, PD, and Stable Disease) is 
descriptive. 
 
2.4.3. Adverse Events (AE) related to treatment 
The analysis of the occurrence and severity of adverse events related to the treatment is 
also descriptive and any dose adjustment is always to be considered. All patients who have 
received at least one infusion of Fludarabine should be evaluated. 
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3. RESULTS 
 
3.1. Patients Characteristics 
 
A total of 877 patients were registered into the study between 1997 and 2004, 728 of them 
fitted to the inclusion and exclusion criteria, thus then underwent risk stratification, the 
youngest patient at the beginning of the trial was 32 years old, the oldest 81 years old, the 
average age was 59,7 years old. 60.4% were male patients. 535 Patients (73%) were 
classified into the low-risk group (cohort 3), the other 193 (27%) into the high-risk group 
(cohort I, 98 patients and cohort II, 95 patients) 
 
Below is once again the CLL-1 study design placed, this time with the numbers of patients 
from each cohorts.  
 
 
 
Fig.2: CLL1-Study design with patient numbers 
Binet stage A
n=877
RISK STRATIFICATION
n=728
Low risk
n=535
(73%)
High risk
n=193
(27%)
RANDOMIZATION
Watch and wait
HR-F 
Fludarabine*
n=98
HR-WW 
Watch and wait
n=95
*Fludarabine i.v. 25 mg/m2/d, day 1-5, every 28 days
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The following table gives an overview of the characteristics from the high risk patients 
(n=193) included in this analysis. 
 
Table 5: Patients characteristics on trial begin 
Characteristics HR-F HR-WW p-value 
Age (y; median) 60 62 n.s. 
Sex (male) 61.2 % 72.6 % n.s. 
ECOG (PS)*    0 
                   >1 
85.2% 
14.8% 
92.3% 
7.7% 
n.s. 
B-symptoms 9.3% 10% n.s. 
Comorbidities 39.8% 45.2% n.s. 
LN cervical 33% 28.4% n.s. 
LN axillar 22.1% 14.1% n.s. 
LN inguinal 15.9% 6.7% n.s. 
Splenomegaly 11.8% 10.3% n.s. 
Hepatomegaly 3.7% 4.1% n.s. 
WBC count, x109/L (range) 36.2 (6.4-249.4) 26.8 (4.6-184) n.s. 
ALC, x109/L (range) 30.5 (3.2-244.4) 21.8 (0-162.8) n.s. 
HGB level, g/dL (range) 14.1 (10.5-18.1) 14.2 (10.7-17.3) n.s. 
PLT count, x109/L (range) 171 (102-352) 195 (111-418) n.s. 
BM Lymph, % (range) 67% (5-100) 70% (0-100) n.s. 
* Also see: Appendix 
 
Comparison of patients in both arms indicated no significant difference regarding the main 
clinical features and the risk categories. 
 
3.2. Dose of study medication and duration of therapy 
 
Patients randomized into the treatment arm (cohort I) will receive following medication:  
 
Fludarabine 25 mg/m2/day as a 30-minutes i.v. infusion from day 1-5 
 
Cycle repeat on day 28 
  
Study medication will be given for at least 2 cycles, but not more than 6 cycles. Interim 
stagings are scheduled after 2 and 4 cycles of therapy (month 2 and 4). The number of 
treatment cycles is based on the following guideline: 
 
 Complete Remission (CR) after 2 cycles: Administration of another 2 cycles (totally 
4) Fludarabine 
 Complete Remission (CR) first after 4 cycles: Administration of another 2 cycles 
(totally 6) Fludarabine 
 Partial Remission (PR) after 4 cycles : Administration of another 2 cycles (totally 6) 
Fludarabine 
 Progression after 2 or more cycles: Therapy stop 
 No change after 2 cycles: Administration of another 2 cycles Fludarabine 
 No change after 4 cycles: Therapy stop 
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Each treatment cycle takes one month; the maximum duration of therapy for cohort I 
patients is thus 6 months long.  
 
3.3. Response to treatment with Fludarabine (also see chapter 2.3.2.1) 
 
 
Table 6: Response rate to Fludarabine 
Response to Fludarabine (n=74) 
ORR CR PR SD PD 
85% 
32% 
24 pts 
53% 
39 pts 
7% 
5 pts 
8% 
6 pts 
 
The evaluation of the response according to the NCI-WG guidelines of 1996 to Fludarabine 
was possible for totally 74 patients who really received the therapy. An overall response 
rate of 85 % from these patients was reached, with higher partial remission rate (PR 53%) 
than the complete remission rate (CR 32%). 
 
3.4. Side Effects of Fludarabine 
 
Being used to help evaluate the side effects of Fludarabine was the CTC (Common Toxicity 
Criteria), a standardized classification of side effects used in assessing drugs for cancer 
therapy. Most US and UK drug trials base their observations on this system which has a 
range of grades from 1-5. Specific conditions and symptoms may have values or 
descriptive comment for each level, but the general guideline is as following:  
 
10-mild 
20-moderate 
30-severe 
40-life threatening 
50-lethal  
 
The evaluation was done after each cycle of Fludarabine administration. Below are listed 
some of the severe side effects of CTC grade 3 or 4.  
 
Table 7: Review of the side effects of Fludarabine 
Main Toxicities (CTCo 3 and 4) 
CTC
0 
3
0 
4
0 
Total 
WBC (White Blood Count) 7 0 7 
Infections 3 0 3 
HGB (Hemoglobin level) 1 1 2 
PLT (Platelet level) 1 1 2 
Thrombosis 2 0 2 
Granulocytes 1 0 1 
Systemic panepidermic lesion 1 0 1 
Arrhythmia 1 0 1 
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Hypokaliaemia 1 0 1 
Lymphocytes 1 0 1 
Bilirubine 1 0 1 
Appetite loss  1 0 1 
Urinary retention 1 0 1 
Categorically seen there are totally 4 main aspects of side effects, which are described in 
the table below. 
 
Table 8: Fludarabine side effects by category (CTC0 1-4) 
Side Effect Hematological Infections Gastrointestinal Neurologic 
Number 68 29 29 12 
Percentage 37% 16% 16% 7% 
 
Hematological side effects were the most among all the side effects, ranging from anemia, 
leucopenia, neutropenia and thrombopenia, followed by infections and gastrointestinal side 
effects.  
 
3.4.1. Hematological side effects 
 
One of the most common side effects of Fludarabine is myelosupression (Bergmann 1993, 
Wijermans 1993). Furthermore possible side effect is an increase of the occurrence of 
Fludarabine-associated autoimmune hemolytic anemia (AIHA), from 4 till 21 % of the 
patients. Autoimmune thrombopenias (AITP) are also possible (Mauro et al 2000, Hamblin 
et al 1986, De Rossi et al 1988, Byrd et al 1994, Di Raimondo et al 1993, Myint et al 
1995). 
 
Anemia was the least among the hematological side effects with 9%. Leucopenia had a 
higher rate with 56%, while thrombopenia had 35%. 
 
3.4.2 Gastrointestinal side effects 
 
Gastrointestinal side effects, for example nausea, vomitus, diarrhea, stomatitis remain as 
common side effects of the most antineoplastic drugs. The gastrointestinal side effects 
were mainly mild. There were no gastrointestinal symptoms of CTC grade 3 or 4; all 
gastrointestinal side effects were only CTC grade 1 or 2, thus representing themselves as 
mild till moderate side effects.  
 
Table 9: Gastrointestinal side effects 
Gastrointestinal side effects 
CTC0 10 20 30 40 
Nausea 5 7 0 0 
Vomitus 1 8 0 0 
Diarrhea 1 3 0 0 
Stomatitis 3 0 0 0 
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3.4.3. Neurological side effects 
 
Occurrence of neurotoxicity through Fludarabine therapy in CLL patients were described in 
some cases (Zabernigg 1994, Johnson 1994). 
Listed in the CTC-criteria among the neurologic side effects are for example sensory, sleep 
disorders, motorics, consciousness, coordination, affect, headache, vertigo, behavior 
disorder, hearing and sight. 
  
Table 10: Neurological side effects 
Neurological side effects 
CTC0 10 20 30 40 
Sensory 1 0 0 0 
Motorics 1 0 0 0 
Affect 1 0 0 0 
Headache 4 2 0 0 
Vertigo 4 0 0 0 
Sight 1 0 0 0 
 
Most of the neurological side effects were in the category CTC grade 1, which represent 
mild symptoms; none were in the higher CTC grade (30 or 40). Headaches and vertigo were 
the most among them.  
 
3.4.4. Other side effects 
 
Apart from the common side effects mentioned above, there are also other 
uncommon/seldom side effects which occurred in a small number of the patients, such as 
coughing, skin lesions, elevation of liver enzymes, arrhythmia, thrombosis, dyspnoea, loss 
of appetite, urinary retention and allergic reaction.  
 
Another main aspect of side effects, the infections, took the second place together with the 
gastrointestinal side effects among the side effects after the group of hematological side 
effects.  
Infections during a therapy with Fludarabine are common especially because of the vast T-
cell depressions (Bergmann et al 1993, Wijermans et al 1993). Included in the group of 
infections were the following, based on the CTC-criteria, symptoms: fever, infections, and 
chilling.   
 
Table 11: Infection rate 
 HR-F HR-WW 
Infections 23.5% 9.6% 
 
Table 12: Etiology of the infections 
Etiology of the infections 
Etiology bacterial viral mycotic other 
Percentage  42.4% 51.5% 2.2% 3.9% 
 HR-F HR-WW HR-F HR-WW HR-F HR-WW HR-F HR-WW 
 45.3% 44.0% 43.4% 52% 1.9% 0% 9.4% 4% 
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As seen in the table above, there were more infections registered in the cohort I (treatment 
arm) in comparison with cohort II (watch and wait arm) with 23.5% vs. 9.6%. Viral 
infections were the most, followed by bacterial infections, but none of them reached the 
CTC0 4, while 3 of them reached the CTC0 3. 
 
3.4.5. SAE (Severe Adverse Events) 
 
AE (Adverse Events) which match the criteria defined below are recorded as serious/severe 
adverse events (SAE): 
 Fatal (results in death; NOTE: death is an outcome, not an event!) 
 Life threatening (NOTE: the term refers to an event in which the patient was at 
immediate risk of death at the time of the event, it does not refer to an event which 
could hypothetically have caused death had it been more severe) 
 Disabling 
 Requires hospitalization or prolongation of existing hospitalization 
 Congenital anomaly (birth defect) 
 Medically significant event or event requiring intervention to prevent the outcomes 
listed above. 
 
Occurrence of a SAE does not directly indicate Fludarabine (when administered) as the 
cause behind the SAE, although it is possible. Other probable or common reasons such as 
ischemic stroke or myocardial infarction should always be considered. Possible involvement 
of Fudarabine in the occurrences of SAE should always be assessed.  
 
There were 7 SAE cases reported during the CLL-1 study, which involved 6 males and only 
1 female. Death occurred in 3 events; the other 4 patients survived the SAE (see also the 
table below).  
 
Table 13: Severe Adverse Events (SAE) 
Severe Adverse Events (SAE) 
Outcome : Death Outcome : Survival Total 
3 pts 4 pts 7 pts 
 
SAE resulting in death  
One multi morbid patient died despite having intensive treatment because of acute renal 
failure, cardiac decompensation, together with septic shock due to obstructed kidney with 
ureteral calculus.  
 
Another one died after suddenly falling down in the garden of his house, probably due to 
heart attack, attempts to reanimate him were unsuccessful.  
 
One patient was brought to the hospital due to an unclear, therapy refractory fever and 
reduction of his general condition. The patient received treatment for 3 months, including 
intravenous antibiotics, antifungal agents, blood culture and several other diagnostic 
procedures to find the reason of the fever, unfortunately without satisfying results. 
Substitutions of erythrocytes and platelets were then needed to keep him stable. 
Considering all the clinical findings and the development of more abdominal lymphomas in 
course of the treatment, it was assumed that the reason behind the refractory, unclear 
elevation of the body temperature was the combination of B-symptoms due to CLL and 
potentially viral superinfection within the scope of reduced immune system. The patient 
passed away after 3 months of treatment because of multi organ failure.    
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SAE survived by the patients 
One patient had syncope and was then brought to hospital in order to clarify the origin of 
her syncope, which existed anamnestic since 20 years. The event was fortunately without 
any severe or life threatening consequences, another one had epileptic seizure during an 
ischemic stroke of the brain areas supplied by the left middle cerebral artery, the patient 
eventually then recovered from the event.  
 
One patient suffered from dysesthesia of the legs, which later progressed into beginning 
paralysis of the legs, and unspecific sweating tendency.   
 
One life threatening event occurred in one patient two weeks after receiving four months 
long Fludarabine administration, the patient was brought to the hospital by emergency 
physician due to fever of 40o C. Listeriosis with sepsis and meningitis was later diagnosed 
and with antibiotics medicated.  
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3.5. Progression Free Survival (PFS) under Fludarabine Therapy 
 
The progression free survival (PFS) was evaluated using the Kaplan-Meier method and the 
survival chart using log ranks test (Kaplan & Meier 1958). 96 patients (intent-to-treat 
analysis) from the therapy arm and 94 patients from the “watch and wait” arm were 
included in the PFS evaluation and had follow-up observations. The median observation 
time was for HR-F 44.6 months (95% CI, range: 0-109 months) and for HR-WW 40.0 
months (95% CI, range: 6.9-92 months). 
Below is described the comparison between both cohort I and II in terms of progression 
free survival. A longer time span of PFS (progression free survival) had as expected the 
patients from therapy arm (cohort I) with 27.9 months, whereas the patients from watch 
and wait arm (cohort II) had 15.3 months of PFS time span (p-value = 0.002). This shows 
a benefit of 12 months for the patients receiving Fludarabine. 
 
Diagram 1: PFS HR-F vs. HR-WW 
 
PFS: 
HR-F vs. HR-WW 
27.9 months vs. 15.3 months 
 
 
 
 
 
p-value = 0.002 
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Below is once again the diagram of the PFS (progression free survival), this time with all 
three cohorts included together. Patients from the low-risk arm (cohort III), per definition 
also with less risk and tendency of progressing from Binet stage A to Binet stage B or C, 
had as expected among the three cohorts the best PFS time span (p-value < 0.001)  
 
 
      Diagram 2: PFS HR-F vs. HR-WW vs. LR 
 
 
PFS: 
HR-F vs. HR-WW vs. LR 
27.9 months vs. 15.3 months vs. 64.8 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p-value < 0.001 
 
3. Results                                                                                                                                                             
27  
 
3.6. OS (Overall Survival) under Fludarabine therapy 
 
The comparison between the therapy arm and the “watch & wait” arm regarding OS 
(overall survival) was evaluated also using the Kaplan-Meier method and the survival chart 
using log ranks test (Kaplan & Meier 1958). 
 
      Diagram 3: Overall Survival HR-F vs. HR-WW 
 
 
OS :  
HR-F vs. HR-WW 
Median not yet reached 
 
 
As one could see from the diagram above, in terms of the overall survival no prolongation 
through Fludarabine administration is seen in comparison with cohort II. Fludarabine 
prolongs the progression free survival but not the overall survival. 
p-value = 0.681 
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To complete the comparisons, it is once again described below the comparison between all 
3 cohorts regarding their overall survival rate.  
 
 
 
Diagram 4: Overall Survival HR-F vs. HR-WW vs. LR 
 
 
OS:  
HR-F vs. HR-WW vs. LR 
Median not yet reached 
 
Patients with low progression risk showed the best survival rate among the three cohorts 
(p-value < 0.001). 
 
 
 
 
 
 
 
p-value < 0.001 
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4. DISCUSSIONS 
 
Fludarabine’s effectiveness as a powerful agent for untreated patients with advanced CLL 
was demonstrated in some studies (Keating et al 1993, Leporrier et al 2001). In the year 
2000 Rai et al. published the results of their study, which involved 509 patients between 
1990 and 1994 in order to compare the efficacy of Fludarabine with that of Chlorambucil 
and a combination of Fludarabine with Chlorambucil in the primary treatment of CLL (Rai et 
al. 2000), their findings showed that Fludarabine is superior to Chlorambucil in the initial 
treatment of CLL. The rate of complete remission and the overall rate of response 
(complete remission or partial remission), as well as the duration of the response and of 
progression-free survival were significantly better among them treated with Fludarabine 
than among them with Chlorambucil (20 vs. 14 months), thus being in resonance with the 
results from previous studies. Treatment with Fludarabine plus Chlorambucil produced 
response rates similar to those with Fludarabine alone, but with greater toxicity, thus 
cannot be recommended.  
 
The long period of Chlorambucil era –more than 3 decades with lack of progress and 
persistently low rates of objectively measured responses- came to an end as Fludarabine 
emerged to set the new standard in CLL treatment and challenged physicians to find other 
effective agents that, when combined with Fludarabine, will lead to more incremental 
advances and, ultimately, to increased survival among patients with CLL. 
 
Further hope of increased survival was then brought by the monoclonal antibody Rituximab 
(anti CD-20), as its combination with Fludarabine and Cyclophosphamide (known as 
“FCR”), investigated in studies including one initiated by the German CLL Study Group 
(CLL-8 study), was able to improve response rates and survival rates, therefore setting 
since 2008 a new era in CLL treatment (Hallek et al. 2008). 
 
Patients in early stage of CLL showed, however, till now only unsurely clinical advantage 
regarding an early start of chemotherapy (Dighiero et al 1997, Brugiatelli et al 1995, 
FGCLLG 1990). The question, whether administrations of Fludarabine for patients with CLL 
stage Binet A who have a high risk of progressing to stage Binet B or C would bring clinical 
benefits for them has not found an answer through recent studies and presents itself as the 
base of our CLL-1 study. 
 
Previous studies showed that patients with advanced CLL and first line Fludarabine therapy 
without any previous therapy could reach a progression free survival time span between 25 
to 30 months (Rai et al 2000, Spriano et al 2000, FGCLLG 1999). The evaluation of CLL-1 
study showed a progression free survival time span of 27.9 months for patients with first 
line Fludarabine therapy in early CLL (Binet stage A), thus being in accordance to those 
previous studies.  
 
4.1. Side Effects & Infections 
 
On the top of the adverse events list stood as expected hematological side effects such as 
leucopenia, thrombopenia or anemia like in previous studies.  
Infection rate was higher in cohort I with 23.5% in comparison with 9.6% from cohort II, 
likely also due to the myelosupression through Fludarabine, thus resulting in somewhat a 
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weaker immune system of those Fludarabine-treated patients. Fortunately though, none of 
these infections reached the CTC grade 4, while only 4 times was CTC grade 3 reached. 
They were largely mild or moderate infections, thus do not display a hurdle against the 
application of Fludarabine in CLL stage A patients with high progression risk.  
 
In order to win an overview of the extent of possible side effects caused by Fludarabine, we 
compared the CLL-1 study with another study also initiated by the GCLLSG (CLL-4 study)  
which has some design similarities with CLL-1 study, as it evaluated the usage of 
Fludarabine vs. the combination of Fludarabine and Cyclophosphamide in indolent CLL Binet 
stage A patients, and with some other previous studies and also the official Fludarabine 
product information in terms of the side effects of Fludarabine. The Fludarabine product 
information inserted 2 single-arm open-label clinical studies involving 133 patients 
conducted by M.D. Anderson Cancer Center (MDAH) and by the Southwest Oncology Group 
(SWOG) which evaluated Fludarabine administration in adult patients with CLL refractory to 
at least one prior standard alkylating-agent containing regimen. 
 
4.1.1. Hematological side effects. 
Myelosuppression is renowned as a major side effect of therapy with Fludarabine. 
Hematological side effects made the most of all side effects in this study with 37%. 7% (of 
all cases) reached even the CTC grade 3 or 4. Almost 70% of the patients had 
hematological side effects, thus confirming the general assumption. A lower rate of 39.4% 
was reported by Eichhorst et al. in the CLL-4 study (from a total of 173 patients), this can 
be explained by recognizing that Eichhorst et al published only the ones reaching CTC 
grade 3 or 4, while CLL-1 study recorded those with grade 1 or 2 as well.  
 
Biggest impact of Fludarabine therapy is felt concerning the leucopenia, weighing 56% of 
the hematological AE. 13% of the hematological AE were severe leucopenias (severe 
means that the AE reach CTC grade 3 or 4), CLL-4 study reported that 26% of their 
patients had severe leucopenias reaching CTC grade 3 or 4. This fairly big difference (CLL-1 
study recorded only 9.2%) is likely due to the patients collective in the CLL-4 study which 
were Binet B or C patients or at least Binet A patients with B-symptoms, meaning the 
patients had more “advanced” CLL than our patients with only Binet A patients. Fludarabine 
product information stated in the study done by MDAH and SWOG that 59% of the patients 
endured neutropenia, which indirectly also reflects a part of leucopenia.  
 
Thrombopenia presents itself as the second most common hematological AE under 
Fludarabine therapy. CLL-1 study showed that thrombopenia took 35% fraction of the 
hematological AE, and around 24% of the patients suffered it, severe thrombopenia had 
however only 2% of the patients, thus playing only a minor role. CLL-4 study recorded 
12.7% thrombocytopenias among their patients. 
 
Anemias due to Fludarabine therapy in this study were with only 9% the most seldom 
among the hematological AE and made only 6% of the patients. 11.6% of the patients in 
the CLL-4 study were reported having anemia. 
 
4.1.2. Infections 
8.7% of the patients in the CLL4-study had infection (again only those with CTC grade 3 or 
4 were reported), and showed no difference against the FC (Fludarabine + 
Cyclophosphamide) arm, in a sense maybe because both arms obtained Fludarabine. In 
CLL-1 study the rate of infections in the Fludarabine arm was higher than in the “watch and 
wait” arm (23.5% vs. 9.6%). The impact of the infections in CLL-1 study was under 
control, as none of them reached the CTC0 4, while only 3 of them reached the CTC0 3, 
bolstering the suggestion that Fludarabine is feasible for CLL patients.  
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The studies described in the Fludarabine product information showed infection rate of 33% 
and 44% in the MDAH (N=101) and, respectively, in the SWOG (N=32) study, higher than 
in CLL-1 study. It is however to remember that the patients collective in the MDAH and 
SWOG studies were those with CLL refractory to at least one prior standard alkylating-
agent containing regimen, while in CLL-1 study the patients were all without any previous 
CLL therapy.   
 
4.1.3.  Gastrointestinal side effects 
Adverse events concerning the digestive tract, particularly nausea and vomiting are on the 
one hand in fact common and occur frequently during chemotherapy. On the other hand, 
they are in most cases objectively mild, though subjectively were without any doubt very 
uncomfortable for the patients.  
Gastrointestinal side effects were the least among the adverse events in the CLL-4 study, 
making just 1.7% of the patients, however, those AE reached CTC grade 3 or 4, while the  
29% recorded in the CLL 1 study represented only CTC grade 1 or 2, thus were all mild or 
moderate. 46% was noted in the Fludarabine product information based on the MDAH 
study with nausea/vomiting once again playing the biggest part.  
 
4.1.4.  Neurological side effects 
CLL-1 study evaluated that neurological side effects as a group were among the least in 
CLL-1 study, and most of them were only grade 1 (CTC) with headache and vertigo playing 
the biggest part among them. This fact suggests too that Fludarabine is in terms of 
neurotoxicity very feasible. CLL-4 study supports this idea, as no neurological side effects 
were published in the paper from Eichhorst et al., but this does not mean that there were 
no neurological side effects in CLL-4 study at all, it is explainable because only AE that 
reached CTC grade 3 or 4 were published in the paper.  21% of the patients in the study 
done by MDAH (stated in Fludarabine product information) had neurological adverse events 
with weakness being the most among them.  
 
While Fludarabine was connected with the appearance of severe neurologic effects including 
blindness, coma, and death, one shall notice that they appeared in patients treated with 
high doses of Fludarabine in dose-ranging studies in patients with acute leukemia (the dose 
was approximately four times greater (96 mg/m2/day for 5 days) than the recommended 
dose of 25 mg/m2/day for 5 days). 13 of 36 patients treated with the higher dose regime 
developed this severe neurotoxicity, according to the study noted in the product 
information. Used at the normal, recommended dose, like in CLL-4 or CLL-1 study, no such 
severe neurologic effects as stated above were noticed, suggesting that the dose used in 
both study is a feasible Fludarabine dosage for treating chronic lymphocytic leukemia.  
 
4.2. SAE (Severe Adverse Events) 
 
Interesting is also the theme severe adverse events (SAE) during CLL-1 study, and the 
question whether Fludarabine usage a direct correlation with those events has or not, or 
even turns out to be the main causal reason behind those seven events.     
 
In the 3 SAE eventually leading to death, direct correlation between them and Fludarabine 
usage was evaluated as “unlikely”, as one died because of urosepsis due to ureter calculus 
which then resulted in many organ complications, another one died most likely because of 
cardiac problems with history of former myocardial infarction. 
 
The last patient died due to a therapy refractory fever, later interpreted as refractory B-
symptoms due to progressive CLL with obvious growth of his abdominal lymphomas. 3 
times Fludarabine administration were then given, unfortunately without positive response.  
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Here too is a causal connection with Fludarabine as “unlikely” interpreted, the fever existed 
already before the Fludarabine administration and was actually together with the abdominal 
lymphomas the reason behind the Fludarabine usage. 
 
In 2 patients, who survived their SAE, one with epileptic seizure due to ischemic stroke and 
the other with syncope which existed supposedly since 20 years, again no “likely” direct 
correlation between Fludarabine usage and their SAE was found.  
 
A “possible” correlation between Fludarabine usage and one life threatening SAE was 
interpreted in 1 patient, who, 2 weeks after receiving the third cycle of Fludarabine (i.v. 45 
mg), started to develop persisting dysesthesia of the legs with unspecific sweating 
tendency without fever, which after another 10 days progressed into beginning paralysis of 
the legs thus requiring thorough treatment in the intensive care unit. 
Another possible correlation was found in one other patient, the correlation this time 
actually as “likely” interpreted. The patient was brought to the clinic by emergency 
physician due to fever of 40o C 2 weeks after the last Fludarabine (50 mg i.v.) treatment. 
Sepsis and meningitis were diagnosed with Listeriosis as the main reason behind them. 
Antibiotics were required to bring the life threatening SAE under control.  
 
4.3. Response rates 
 
Fludarabine, given at 25 mg/m2/day i.v. for 5 days long with cycle repeat on day 28 is now 
not only the most effective mono therapy for treating CLL, it has now established itself as 
the base agent in developing the right chemotherapy combinations for CLL, such as in the 
CLL-4 trial which evaluates the combination of Fludarabine plus Cyclophosphamide and CLL-
8 study which evaluates the “FCR” combination (Fludarabine plus Cyclophosphamide plus 
Rituximab).  
 
Response rates achieved by Fludarabine mono therapy surpassed those achieved by other 
agents also used as mono therapy. Chlorambucil, as the old standard therapy for CLL, was 
evaluated by Dighiero et al in terms of response rates, and reported an ORR of 76% 
(Dighiero et al. 1998). The result from a study done by FCGCLL in 1990 reported a similar 
ORR (68%). Several studies evaluating Fludarabine given as first line CLL therapy showed 
an overall response rate between 63% and 80%, and complete remission rate between 20-
46% (Leporrier et al 2001, Spriano et al 2000, Rai et al 2000, O`Brien et al 1998, FCGCLL 
1996), higher than the rate achieved by Chlorambucil. 
 
CLL-1 study registered an overall response rate of 85%, complete remission rate was 32%, 
partial remission rate was 53%, thus being in consistent accordance with the other 
published studies. 15% of the patients were non-responders (7% had stable disease and 
8% had progression). 
CLL-4 study, initiated by Eichhorst et al., noted a similar ORR with 82.9%, however with an 
obvious lower CR rate of 18.3%. One possible explanation for this particular difference is 
that patients with more advanced Binet stage C disease were included in the study, while 
all the patients in CLL-1 study had Binet stage A disease.  
 
4.4. Progression Free Survival (PFS) 
 
CLL-1 study showed that Fludarabine, given in patients with Binet stage A CLL, were able to 
induce a prolongation of the progression free survival in comparison with the “watch and 
wait” arm, with 27.9 months vs. 15.3 months (p-value = 0.002), respectively, for both 
arms.  
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Other publications showed that patients, with advanced CLL though, who were treated with 
Fludarabine gained a progression free survival time span between 25 and 30 months, thus 
once again standing in harmony with the result from CLL-1 study (Rai et al 2000, Spriano 
et al 2000). CLL-4 study showed a median PFS of 20 months for the Fludarabine arm. 
 
One can say that a positive effect of Fludarabine in terms of PFS does exist not only in 
patients with advanced CLL, but also in patients with Binet stage A CLL as seen in CLL-1 
study.    
 
4.5. Overall Survival (OS) 
 
No significant difference or advantage is seen between cohort I and cohort II in terms of 
the overall survival. This could indicate that maybe the median observation time were not 
long enough to foresee the advantages Fludarabine could bring forth, or could also suggest 
that Fludarabine, despite able to give patients significant advantages in terms of their 
Progression Free Survival (PFS) time span, does not prolong the Overall Survival (OS) time 
span.  
 
Summing-up things, there is a positive impact of a first line Fludarabine therapy in CLL 
stage A patients with high risk of disease progression unto stage Binet B, first of all 
concerning the aspect of progression free survival, which were prolonged in comparison 
with patients without any therapy. There is, however, a setback, because no advantage in 
terms of overall survival (OS) could be seen, as it is not prolonged through Fludarabine.  
 
The findings and comparisons of the AE in several different studies are, as one can see, 
consistent and not contradictive; they support each other’s findings. Looking further into 
the aspect of the impact made by those adverse events, they remain so far under control 
and relatively manageable, with no major handicap for Fludarabine in comparison with 
“watch and wait” strategy, one could say then that the use of Fludarabine is safe and 
feasible in Binet stage A of chronic lymphocytic leukemia.  
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5. CONCLUSIONS 
 
The much longed cure for chronic lymphocytic leukemia has, despite decent improvements 
of chemotherapy regimes recently, until today unfortunately not yet been discovered. 
Fludarabine, an alkylator from the purine analogue type, showed itself in previous studies 
as a powerful option, whether used as a monotherapy or as part of a therapy combination 
with other antineoplastic drugs, such as Cyclophosphamide, or the much promising 
newcomer “Rituximab” from the group monoclonal antibody (anti CD-20), which recently 
has set a new dawn of hope for CLL patients, as it brought the new therapy standard since 
2008 (in combination with Fludarabine and Cyclophosphamide, also known as the “FCR” 
chemotherapy) for physically fit CLL patients.  
 
Particular information, however, concerning the efficacy of Fludarabine in CLL stage Binet A 
patients with high risk of progressing into Binet stage B still unfortunately lack. CLL-1 study 
would then be one of the first providers of information concerning this aspect.  
 
CLL-1 study intended therefore to answer the question, whether administrations of 
Fludarabine as a monotherapy in CLL stage A patients with high risk of progression would 
bring an advantage for the patients in comparison with the until now standard option, 
which is the “watch and wait” strategy.  
 
The evaluation was based on the response to Fludarabine (including complete response, 
partial response, or no response, meaning a stable disease or progression), AE (adverse 
events), SAE (severe adverse events), PFU (progression free survival), and also not to 
forget the overall survival rate. From the total of 193 patients stratified as CLL stage A 
patients with high progression risk, 98 patients were randomized into the therapy arm as 
cohort I, while the remaining 93 patients into the “watch and wait” arm as cohort II. 
Cohort III included Binet stage A patients with low risk of progressing into Binet stage B; 
these patients, too, receive no treatment.   
 
Patients who received Fludarabine (25 mg/m2/day for 5 days, maximum 6 cycles) had quite 
a high overall response rate with 85% (complete remission rate was 32%, partial remission 
rate was 53%), only 8% had progression, 7% stable disease.  
They also showed after a median observation time from 44.6 months a prolonged 
progression free survival time span of 27.9 months, compared with patients from “watch & 
wait” arm with progression free survival of 15.3 months after a median observation time 
from 40 months (p-value: 0.002). 
 
Looking at the comparison concerning the overall survival between both arms, no 
advantage of prolongation for the therapy arm could be noticed though; suggesting that 
Fludarabine is unable to induce a prolongation of the overall survival time span, or maybe 
that a longer median observation time is needed to determine a survival benefit for any 
first-line regimen.  
 
Infection rate was higher in the therapy arm than in the “watch and wait” arm (23.5% vs. 
9.6%); most of them were mild though. Other adverse events rates were in accordance 
with the findings of previous trials and remain tolerable. 
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Summary:  
 
Fludarabine is feasible, prolongs the progression free survival but not the overall survival in 
CLL Binet A patients with high risk of progressing into Binet stage B or C. The “watch and 
wait” strategy cannot therefore be replaced by Fludarabine administration and remains as 
the standard therapy option for CLL Binet stage A patients with or without high risk of 
progressing into Binet stage B or C.      
 
Further improvement may be possible with the use of the chemoimmunotherapy 
combination “FCR” (Fludarabine + Cyclophosphamide + Rituximab), which was the subject 
of the CLL-7 study and the CLL-8 study initiated by the German CLL Study Group and is 
now the new standard therapy for physically fit and advanced CLL patients. The results 
showed that the FCR combination has the best ORR (overall response rate), even better 
than the former standard therapy, which was FC (Fludarabine and Cyclophosphamide). 
Whether FCR could improve the progression free survival and the overall survival in CLL 
Binet stage A patients with high risk of progressing, shall be cleared in further upcoming 
trials.  
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Table   1: Rai staging of CLL (Rai et al. 1975)   
Table   2: Binet staging of CLL (Binet et al. 1981) 
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Diagram 4: OS (Overall Survival) HR-F vs. HR-WW vs. LR 
 
Figure 1: Simplified CLL-1 study design 
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9. Appendix                                                                                                                                                                   
46  
 
 
 
9. Appendix 
 
Appendix 1: ECOG Performance Status 
 
Table 14: ECOG performance status scale 
ECOG Performance Status 
Score Description 
0 Asymptomatic (Fully active, able to carry on all pre-disease activities without 
any restriction)  
1 Symptomatic but completely ambulatory (Restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary 
nature. For example, light housework, office work)  
2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self 
care but unable to carry out any work activities. Up and about more than 50% 
of waking hours) 
3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-
care, confined to bed or chair 50% or more of waking hours)  
4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair)  
5 Death  
 
“ECOG (PS)”, stated above, represents the “performance status” of the patients according 
the criteria used by ECOG (Eastern Cooperative Oncology Group) (Oken et al 1992). This 
ECOG score (also called the WHO or Zubrod score) runs from 0 to 5, with 0 denoting 
perfect health and 5 death.  
 
The performance statuses were analyzed ahead of the therapy in every patient. Patients 
with an ECOG-status of more than 2 would not be able to meet the inclusion criteria and 
therefore would then be excluded from the study.  
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Appendix 2: Flow sheet of the CLL-1 study 
 
 Fig. 3: CLL-1 study flow sheet 
Flow sheet CLL-1 study 
CLL Binet A, high progression risk
No Yes
Randomization
Cohort III
Watch and wait
Cohort I
Fludarabine 25 mg/m2/d, d1-5
Cycle repeat on day 28
Max. 6 cycles
Cohort II
Watch and wait
Initial diagnostics Initial diagnostics
Follow up:
- Month 3
- Month 6
- Month 9/12/18/24
End of study report
- Cycles 1+2
CR,PR,SD
- Cycles 3+4
CR, PR                         (SD)   PD
- Cycles 5+6
End of therapy
End of therapy report
(2 months after end of therapy)
Restaging
Annual observation every 12 months
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